Mar B, Bullinger L, McClean K, Grauman P, Harris M, Stevenson K, Neuberg D, Sinha A, Sallan S, Silverman L, Kung A, Nigro L, Ebert B, Armstrong SA. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nature Communications. 2014 Mar 24;5:3469. [PMCID:4016990]

Santos M, Faryabi R, Ergen A, Day A, Malhowski A, Canela A, Onozawa M, Lee J, Callen E, Gutierrez-Martinez P, Chen H, Wong N, Finkel N, Sharrow S, Rossi D, Ito K, Ge K, Aplan P, Armstrong SA, Nussenzweig A, , DNA-damage induced differentiation of leukemic cells as an anti-cancer barrier. Nature, advanced online publication 2014 Jul 27.

Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J, Levine JE, Wang J, Hahn WC, Gilliland DG, Golub TR, Armstrong SA. Transformation from committed progenitor to leukaemia stem cell initiated by MLL AF-9. Nature. 2006: 442, 818-22.

Wei G, Twomey D, Lamb J, Agarwal J, Stam R, Opferman JT, Sallan SE, den Boer ML, Pieters R, Golub TR, Armstrong SA. Gene expression-based chemical genomics identifies rapamycin as a modulator of glucocorticoid resistance. Cancer Cell. 2006: 10, 331-42.

Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU, Xia X, Jesneck J, Bracken AP, Silverman LB, Kutok JL, Kung AL, Armstrong SA. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell. 2008 Nov 4; 15(5):355-68.

Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z, Zon LI, Armstrong SA. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science. 2010 Mar 26;327(5973):1650-3.

Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J, Johnson LD, Scott MP, Smith JJ, Xiao Y, Jin L, Kuntz KW, Chesworth R, Moyer MP, Bernt KM, Tsend JC, Kung AL, Armstrong SA, Copeland RA, Richon VM, Pollock RM. Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor. Cancer Cell 2011, Jul 12;20(1)53-65.

Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, Feng Z, Punt N, Daigle A, Bullinger L, Pollock RM, Richon VM, Kung AL, Armstrong SA. MLL-rearranged Leukemia is Dependent on Aberrant H3K79 Methylation by DOT1L. Cancer Cell 2011, Jul 12;20(1)66-78.

Onder TT, Kara N, Cherry A, Sinha AU, Zhu N, Bernt KM, Cahan P, Mancarci OB, Unternaehrer J, Gupta PB, Lander ES, Armstrong SA, Daley GQ. Chromatin-modifying enzymes as modulators of reprogramming. Nature. 2012 Mar 4;483(7391):598-602.

Neff TA, Sinha AU, Kluk MJ, Zhu N, Khattab M, Stein L, Zie H, Orkin SH, Armstrong SA. Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Proc. Natl. Acad. Sci. 2012 Mar 27;109(13)5028-33.

Heidel FH, Bullinger L, Feng Z, Wang Z, Neff TA, Stein L, Kalaitzidis K, Lane SW, Armstrong SA. Genetic and Pharmacologic Inhibition of β-Catenin Targets Imatinib Resistant Leukemia Stem Cells in CML. Cell Stem Cell, 2012 Apr 6;10(4)412-24.

Kalaitzidis D, Sykes SM, Wang Z, Punt N, Tang Y, Ragu C, Sinha AU, Lane SW, Souza AL, Clish CB, Anastasiou D, Gilliland DG, Scadden DT, Guertin DA , Armstrong SA. 2012. mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. Cell Stem Cell, (1934-5909), 2012 Sept 07; 11 (3)429.